ALMKT:EPA
Mauna Kea Technologies SA
€0,088
arrow_downward
-1,02%(-0,00090) 1D
19 ພ.ຈ., 11 ໂມງ 25 ນາທີ 50 ວິນາທີ GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0,09
High
€0,09
Low
€0,09
Mkt. cap
17,60 ລ້ານ
Avg. vol.
472,14 ພັນ
Volume
105,13 ພັນ
P/E ratio
0,75
52-wk high
€0,23
52-wk low
€0,07
EPS
€0,12
Shares outstanding
195,26 ລ້ານ
No. of employees
56
Open
€0,09
High
€0,09
Low
€0,09
Mkt. cap
17,60 ລ້ານ
Avg. vol.
472,14 ພັນ
Volume
105,13 ພັນ
P/E ratio
0,75
52-wk high
€0,23
52-wk low
€0,07
EPS
€0,12
Shares outstanding
195,26 ລ້ານ
No. of employees
56
News stories
From web sources and news partners
Business Insider
·
21 ນາທີກ່ອນ
Why Morgan Stanley Says the S&P 500 Is Poised to Jump 18%
The Motley Fool
·
39 ນາທີກ່ອນ
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
Barron's
·
10 ຊົ່ວໂມງກ່ອນ
Generac Jolted After Nvidia Earnings. Why It’s a Top S&P 500 Stock Today.
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA
CEOSacha Loiseau
Employees56
Founded2000
Headquarters-
SectorHealth Care
IndustryMedical device
Websitemaunakeatech.com